Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of etentamig and iberdomide treatment for patients with relapsed or refractory multiple myeloma

Verified siteInvestigationalNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on treating Multiple Myeloma that has returned or stopped responding to previous treatments, known as Relapsed/Refractory Multiple Myeloma. Multiple Myeloma is a type of blood cancer that affects plasma cells, which are cells in the bone marrow that help fight infections. The study will test a combination of two medications: etentamig and iberdomide (also known as CC-220).

The purpose of this research is to understand how safe and tolerable these medications are when given together, and to find the most appropriate dose combination for patients. During the study, patients will receive etentamig along with iberdomide capsules taken by mouth. Some patients will also receive iberdomide through an eye drop solution, while others will receive it through intravenous administration (given directly into a vein).

The study will monitor how patients respond to the treatment by checking if the cancer improves, stays the same, or gets worse. Doctors will track various aspects of the disease response, including how long the treatment works and whether any cancer cells remain in the body. Throughout the study, patients will have regular check-ups to monitor their health and any side effects from the treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial evaluation

    Your diagnosis of Relapsed/Refractory Multiple Myeloma (RRMM) will be confirmed through laboratory tests

    Your physical condition will be assessed using the ECOG performance scale (a measure of your ability to perform daily activities)

    Laboratory tests will be conducted to measure your disease levels

  2. Step 2

    Treatment administration

    You will receive two medications during the study:

    Etentamig administered through intravenous infusion (through a vein)

    Iberdomide taken as oral capsules

    The doses of both medications will be determined during the study

  3. Step 3

    Monitoring phase

    Regular assessments will track your response to treatment through:

    Blood tests to measure disease levels

    Evaluation of any side effects

    Measurement of remaining disease levels in your body

    Assessment of how long the treatment remains effective

  4. Step 4

    Response evaluation

    Your response to treatment will be classified as one of the following:

    Partial Response (PR): some improvement in disease levels

    Very Good Partial Response (VGPR): significant improvement in disease levels

    Complete Response (CR): no detectable disease using standard tests

    Stringent Complete Response (sCR): most thorough level of disease elimination

  5. Step 5

    Long-term follow-up

    Monitoring will continue to track:

    How long the treatment effects last

    Time until the disease shows signs of returning

    Your overall health status

    The study may continue until March 2036

Who can join the trial?

6 criteria

  • Age requirement: Adults aged 18-64 years old and elderly people aged 65 and above can participate
  • Must have a confirmed diagnosis of Multiple Myeloma that has returned or not responded to previous treatment
  • Must have a good level of physical fitness and ability to perform daily activities, scoring either:
    • 0 (fully active, able to perform all activities without restriction) or
    • 1 (restricted in physically strenuous activity but able to walk and do light work) on the ECOG scale
    • Must have measurable disease that can be evaluated through laboratory tests
    • Both men and women can participate in the study

Who cannot join the trial?

14 criteria

  • Prior history of plasma cell leukemia (a condition where abnormal plasma cells are found in the blood)
  • Active central nervous system involvement (cancer spread to brain or spinal cord)
  • Previous treatment with iberdomide
  • Known allergic reactions to similar medications
  • Pregnant or breastfeeding women
  • Significant heart problems or uncontrolled high blood pressure
  • Active or chronic infections, including hepatitis B, hepatitis C, or HIV
  • Major surgery within 4 weeks before starting the study
  • Participation in other clinical trials within 28 days before this study
  • Severe kidney or liver problems
  • Any other medical condition that could make participation unsafe
  • Unable to take blood-thinning medications
  • History of other cancers within the past 3 years (except for successfully treated skin cancer or early-stage cancer)
  • Mental conditions that could affect ability to follow study requirements
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Etentamig is an investigational medication being studied for the treatment of multiple myeloma that has returned or stopped responding to previous treatments. It is being tested as part of a combination therapy approach for patients with relapsed or refractory multiple myeloma. Iberdomide is a CELMoD (Cereblon E3 Ligase Modulation) agent that works by affecting the immune system to fight multiple myeloma cells. It belongs to a newer class of drugs that help modify the body's immune response to fight cancer cells. These medications are being studied together to determine how well they work in combination and to find the safest and most effective doses for treating patients whose multiple myeloma has returned or become resistant to other treatments.

What is already known about the treatment

  • Etentamig

    An investigational medication being studied in clinical trials for the treatment of Relapsed/Refractory Multiple Myeloma (RRMM). Currently undergoing Phase 1/2 clinical trials in combination with CELMoD agents, specifically iberdomide, to evaluate its safety and effectiveness in treating multiple myeloma patients who have not responded to or relapsed after previous treatments. The exact mechanism of action and administration method are still under investigation through the clinical trial process.

  • Iberdomide

    A CELMoD (Cereblon E3 Ligase Modulator) agent being studied in combination with etentamig for treating Relapsed/Refractory Multiple Myeloma. This oral medication works by modifying the function of cereblon, a protein involved in the growth of multiple myeloma cells, and is being evaluated to determine its optimal dosing when used in combination therapy. The drug represents a new generation of treatments aimed at providing options for patients whose multiple myeloma has become resistant to standard therapies.

Investigated diseases

Multiple Myeloma - A type of blood cancer that develops in plasma cells, which are white blood cells that normally produce antibodies to fight infections. In this condition, abnormal plasma cells multiply uncontrollably in the bone marrow, forming tumors in multiple bones throughout the body. These cancer cells produce large amounts of abnormal proteins instead of useful antibodies. The disease typically affects the bones of the spine, skull, pelvis, rib cage, and the areas around the shoulders and hips. As the disease progresses, it can interfere with the production of normal blood cells in the bone marrow and can weaken the bones.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2024-512146-41-00Protocol codeM24-555Estimated enrolment135 patientsSponsorAbbVie Deutschland GmbH & Co. KG

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.